Nebilet (Nebivolol)

Nebilet is a selective β1‑adrenergic blocker indicated for cardiovascular conditions that require blood pressure control or improved cardiac function.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure (reduced ejection fraction): improves ventricular performance and decreases hospitalization.
• Left ventricular systolic dysfunction: enhances myocardial relaxation and supports cardiac output.

• Nebivolol selectively antagonizes β1‑adrenergic receptors, reducing heart rate and myocardial contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide synthase, increasing nitric oxide release and causing vasodilation, thereby decreasing peripheral vascular resistance.

Nebilet may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate discomfort.
• Dizziness or light‑headedness: especially on standing.
• Fatigue: feeling unusually tired.
• Bradycardia: slower than normal heart rate.
• Nausea: upset stomach.
• Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia or heart block: may require medical attention.
• Marked hypotension: sudden drop in blood pressure.
• Bronchospasm: difficulty breathing, particularly in asthmatic patients.
• Allergic reactions: rash, itching, or swelling.
• Hepatic dysfunction: abnormal liver enzymes.
• Acute heart failure exacerbation: worsening symptoms of heart failure.

Before starting Nebilet, several safety considerations should be reviewed.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Cardiac function assessment: evaluate for existing bradyarrhythmias or heart block.
• Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchospasm.
• Concomitant beta‑blockers: avoid duplication to prevent excessive β‑blockade.
• Renal or hepatic impairment: dose may need adjustment.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebilet can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Other β‑blockers: additive cardiac depression.
• Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia or AV block.
• Clonidine abrupt discontinuation: may cause rebound hypertension.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels.
• Anti‑arrhythmic agents (class IA/III): heightened risk of conduction disturbances.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance hypotensive effect.
• Diuretics: potential for electrolyte imbalance and excessive blood pressure fall.
• NSAIDs: may attenuate antihypertensive response.
• Digoxin: monitor for bradycardia.
• Alcohol: can increase dizziness and hypotension.